Editas Medicine, Inc.
EDITNASDAQHealthcare● Active
$2.65
$-0.07(-2.40%)
Market Cap$258946127
P/E Ratio—
52W High$4.537
52W Low$1.66
Editas Medicine, Inc. (EDIT) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · EDIT · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($160.06M) | ($237.09M) | ($153.22M) | ($220.43M) | ($192.50M) |
| Depreciation & Amort. | $5.28M | $5.81M | $6.06M | $6.34M | $5.05M |
| Stock-Based Comp. | $10.00M | $21.42M | $19.80M | $29.29M | $43.40M |
| Change in Working Capital | ($31.23M) | $3.45M | ($1.59M) | $8.18M | ($21.41M) |
| Net Cash from Operations | ($165.24M) | ($210.28M) | ($132.18M) | ($177.35M) | ($163.80M) |
| Investing Activities | |||||
| Capital Expenditure | ($0.61M) | ($8.83M) | ($4.72M) | ($4.12M) | ($7.98M) |
| Purchases of Investments | $0.00M | ($86.22M) | ($258.52M) | ($315.19M) | ($408.89M) |
| Sales of Investments | $139.01M | $257.19M | $259.50M | $433.35M | $362.40M |
| Net Cash from Investing | $138.67M | $162.15M | ($3.73M) | $114.07M | ($54.47M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | ($2.87M) | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Financing | $40.47M | $56.03M | $118.04M | $1.28M | $282.11M |
| Free Cash Flow | |||||
| Free Cash Flow | ($165.85M) | ($219.11M) | ($136.90M) | ($181.47M) | ($171.78M) |
| FCF Margin %(computed) | -409.30% | -678.07% | -175.23% | -920.59% | -672.49% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Editas Medicine, Inc. data
About Editas Medicine, Inc. (EDIT) Cash Flow Statement
Editas Medicine, Inc. generated operating cash flow of ($0.17B) and free cash flow of ($0.17B) for 2025 — a FCF margin of -409.30%. Capital expenditure was ($0.00B).
Frequently asked questions
EDIT · 4 questionsEditas Medicine, Inc. generated free cash flow of ($0.17B) for 2025, up 24.3% year-over-year.
EDIT free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10